MacroGenics, Inc.

240 articles with MacroGenics, Inc.

• MacroGenics, Inc. Hikes Size of Planned IPO to $92 Million

  10/10/2013

• MacroGenics, Inc. to Pour $70 Million Into Two Cancer Drugs

  9/27/2013

• MacroGenics, Inc.' Board of Directors Elects Paulo F. Costa as Chairman

  9/19/2013

• MacroGenics, Inc. Files Paperwork for $60 Million IPO

  9/5/2013

• MacroGenics, Inc. to Receive $10 Million Milestone Payment From Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271

  8/20/2013

• MacroGenics, Inc. Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development

  8/12/2013

• MacroGenics, Inc. Presents Phase 1 Data at American Society of Clinical Oncology Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors

  6/4/2013

• MacroGenics, Inc. Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients With Metastatic Breast Cancer

  5/21/2013

• MacroGenics, Inc.'s DART Platform Grabs Potential $1 Billion Gilead Sciences, Inc. Deal

  1/8/2013

• MacroGenics, Inc. Could Earn More Than $1 Billion Through New Servier Alliance

  9/20/2012

• ImaginAb, Inc. and MacroGenics, Inc. Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer

  9/5/2012

• MacroGenics, Inc. Receives Milestone Payment as Part of Its Global DART™ Alliance With Boehringer Ingelheim Corporation

  12/20/2011

• MacroGenics, Inc. Inks Pharma Deal With Servier Worth Up to $450 Million

  12/1/2011

• The Lancet Publishes Data from Protege, MacroGenics, Inc.' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients

  6/24/2011

• MacroGenics, Inc. Announces Presentation of Protege Phase 3 Clinical Data at American Diabetes Association in San Diego on June 28

  6/23/2011

• Data Published in Blood Demonstrate Potent Activity of MacroGenics, Inc.'s Proprietary DART(TM) Technology

  4/28/2011

• MacroGenics, Inc. Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors

  1/6/2011

• PolyTherics and MacroGenics, Inc. Sign Collaboration Agreement

  12/6/2010

• MacroGenics, Inc. Enters Global Research Collaboration and License Agreement with Pfizer Inc.

  10/27/2010

• Boehringer Ingelheim Corporation and MacroGenics, Inc. Announce Global Alliance to Discover, Develop and Commercialize DART-Based Antibody Therapeutics; MacroGenics Expects to Receive At Least $60 Million and Could be up to $210 Million

  10/26/2010